Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Chronic Obstructive Pulmonary Disease (COPD): An Overview of Contemporary Management and Novel Therapies

Journal Selection Sample Work

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition that significantly impacts quality of life and remains a leading cause of morbidity and mortality worldwide. This overview explores contemporary management strategies and emerging therapeutic approaches for COPD, including pharmacological treatments, inhalation therapies, pulmonary rehabilitation, and advanced interventions. It also highlights novel therapies aimed at improving lung function, reducing exacerbations, and enhancing patient outcomes. The article provides a comprehensive understanding of current clinical practices and future directions in COPD management. In addition, it emphasizes the importance of journal selection and manuscript submission in ensuring effective dissemination of COPD research findings, guiding researchers in choosing appropriate journals and successfully submitting high-quality manuscripts for publication.

An overview of COPD treatment in search of a therapy-focused journal

Management of chronic obstructive pulmonary disease has changed considerably over the past decade. Long-acting bronchodilators remain the foundation of maintenance treatment, single-inhaler triple therapy has become common for patients with frequent exacerbations, and blood eosinophil counts now help decide who benefits from inhaled corticosteroids. Pulmonary rehabilitation is consistently supported by evidence yet under-used, and newer agents — including biologics aimed at type 2 inflammation — are being studied for selected patients.

The manuscript behind this sample, Chronic Obstructive Pulmonary Disease (COPD): An Overview of Contemporary Management and Novel Therapies, reviews that range. Its five keywords — COPD, COPD management, novel therapies, respiratory medicine and pulmonary rehabilitation — point to a clinical, treatment-oriented paper, not an epidemiological or mechanistic one. The journal selection report accordingly looks for open-access respiratory journals with an explicit interest in therapy.

Pulmonary Therapy, The Clinical Respiratory Journal and Therapeutic Advances in Respiratory Disease

The three recommendations are each supported with two articles published in 2026, which is a useful sign that the evidence of fit is current.

  • Pulmonary Therapy (Springer Healthcare) is described as an international, open-access, single-blind peer-reviewed journal covering pulmonary therapies, devices and surgical techniques. One of its examples — a 12-month real-world analysis of single-inhaler triple therapy in COPD — sits squarely within the manuscript's subject.
  • The Clinical Respiratory Journal (John Wiley & Sons) is an open-access journal for clinical research across respiratory medicine, publishing original research, reviews and case studies. Its examples include a multinational survey on extracorporeal carbon dioxide removal.
  • Therapeutic Advances in Respiratory Disease (SAGE Publishing) is identified in the supporting table by its strong focus on new and emerging respiratory therapies. Its examples cover pre-flight assessment in interstitial lung disease and arterial stiffness in asthma.

Reading the journal comparator row by row

The comparator is the centre of this report. All figures below are as reported in the sample; impact factors, charges and editorial statistics are revised each year and must be checked before submission.

ParameterPulm TherClin Respir JTher Adv Respir Dis
Impact factor3.02.33.2
Review duration6–12 weeks59 days15 weeks
Rejection rate50%74–88%75%
APCUSD 7,675 (GBP 5,120)USD 2,430USD 3,000
Word count5,500 (original research); 250-word abstract5,000 (original articles)4,000–6,000
References40–50no strict limitno limit

The impact factors are close, so they do little to separate the options. The real differences lie in cost — the reported charge for Pulmonary Therapy is roughly three times that of The Clinical Respiratory Journal — and in review speed, where the appendix identifies The Clinical Respiratory Journal as fastest at around 59 days.

Cost, reference limits and indexing for authors in India

For a review article, the 40–50 reference range reported for Pulmonary Therapy is the constraint most likely to bite: an overview of contemporary management and novel agents can easily exceed that. Therapeutic Advances in Respiratory Disease, with no reference limit reported, accommodates a fuller evidence base but has the longest reported review time and an acceptance rate given as 4.7%.

The indexing row also mentions that The Clinical Respiratory Journal appears on the UGC-CARE list, alongside SCIE, PubMed/MEDLINE, Scopus and Embase. For many Indian academics this matters for appointments and promotion, and a report written for them should record it. Authors should still confirm current listing status, since such lists are revised.

A further point concerns currency. Reviews of COPD therapy date quickly as new trial results and guideline updates appear, and editors at therapy-focused journals tend to judge an overview by whether its treatment recommendations reflect the latest evidence. Long review times, such as the 15 weeks reported for one title, therefore carry a small risk that the manuscript needs updating before acceptance. Building in a final literature check shortly before submission reduces that risk.

Adapting the comparator approach to another respiratory manuscript

To reuse this sample, keep its order — job sheet and keywords, a reasoned recommendation with recent example articles, a comparator, short rationale-and-scope tables and a five-question appendix on focus, article types, speed and acceptance. Record word and reference limits for the article type you are actually submitting, as many journals allow reviews different lengths from original research. Pubrica prepares these comparisons through its journal selection service; once a journal is chosen, manuscript formatting and scientific editing prepare the review for that journal's requirements.

Questions about this sample

Which shortlisted journal has published the closest match to this COPD review?

Pulmonary Therapy. The report cites a 2026 real-world, 12-month analysis of single-inhaler triple therapy in COPD from the journal, which falls directly within the manuscript's focus on contemporary management. Its scope also covers pulmonary devices and surgical techniques, relevant to the novel therapies the review discusses.

Why does the article processing charge differ so much between these journals?

As reported in the sample, Pulmonary Therapy charges about USD 7,675, against USD 2,430 for The Clinical Respiratory Journal and USD 3,000 for Therapeutic Advances in Respiratory Disease. Open-access fees are set by each publisher and vary widely. Authors should check current fees, institutional agreements and waiver policies before deciding.

Which journal is fastest according to the report?

The appendix names The Clinical Respiratory Journal, with a reported review time of about 59 days. Pulmonary Therapy is given as 6 to 12 weeks and Therapeutic Advances in Respiratory Disease as 15 weeks. These are approximate figures from the time of the report and can vary with reviewer availability.

Why is UGC-CARE listing mentioned in a respiratory journal comparison?

UGC-CARE is a reference list used by many Indian universities when assessing publications for appointments and promotion. The sample notes that The Clinical Respiratory Journal appears on it. For authors in India, recording this helps ensure the chosen journal is recognised by their institution, though listings should be rechecked.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.